The three stocks, from health care and IT sector, with sustained positive return yields have led the investors chasing them closely.
Nanosonics Limited (ASX: NAN) was established in 2000, and together with subsidiaries, is engaged in the research, development, and commercialisation of infection control and decontamination products and related technologies. The company has operations across North America, Australia, Europe, and the Asia Pacific. It is based out of Lane Cove in Australia.
Nanosonics has a market cap of AUD 1.09 billion with ~299.88 million outstanding shares. With the close of the market trading on February 25th, 2019, the NAN stock last traded at a sell-off price of AUD 4.080, soaring high by 12.397%, indicating an intra-day gain of AUD 0.450 with ~2.63 million volume of shares traded. The stock price is quite close to the 52-week high of AUD 4.150 recorded as Day’s High today. Over the past year, the stock performance has been decently positive at 21.81% with the three-month return yield of 22.22% and the six-month return yield of 1.40%. It has also generated a positive YTD return of 30.58% so far.
The company recently updated its 2019 half-year financial results, reporting an increase in both the sales and gross profit to $ 40.69 million and $ 30.58 million, on the corresponding prior period. The cash and cash equivalents also amounted to $ 71.26 million at the end of the period.
Bionomics Limited (ASX: BNO), a clinical stage biopharmaceutical company is engaged in the research and development of novel drug to treat central nervous system disorders and cancer primarily in the United States, Australia and France. The company was established in 1988 and based in Thebarton, Australia.
The company has a market capitalisation of AUD 92.6 million and ~544.69 million outstanding shares. At the close of the market session on February 25th, 2019, the BNO stock’s last sell-off price was quoted at AUD 0.195, up 11.429%, indicating an intra-day gain of AUD 0.020 and 4.17 million shares traded until the end. The stock also generated a positive YTD return of 62.79% so far.
At the end of the half year ended December 31st, 2018, Bionomics reported a strong cash position of $ 27.35 million while cash outflow reflected reduced costs associated with completion of Phase 2 clinical trial of BNC210 in PTSD and cost reductions implemented in the previous year 2017.
Xero Limited (ASX: XRO), together with its subsidiaries, is a global software services company established in 2006. It’s flagship product Xero is a cloud-based accounting software that connects small businesses with their advisors across various business lines like retail, Amazon sellers, hospitality, high tech, legal, non-profit, start-ups and others. It is headquartered in Wellington, New Zealand.
Xero has a market capitalisation of AUD 6.73 billion and ~ 140.72 million outstanding share. As of the last trading session on February 25th, 2019, the XRO stock’ final sell-off price stood at AUD49.050, up 0.677%, indicating an intra-day gain of AUD 0.330. The stock has generated a positive return of 30.30% over the last three months and a positive YTD return of 16.14%. The trending stock price is quite close to the 52-week high of AUD 52.570.
For the financial year 2018, the company had posted operating revenues of $ 406.58 million and EBITDA of $ 26.006 million, both reflecting a year-on-year rise of by 38% and $ 54.6 million respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.